<DOC>
	<DOCNO>NCT01687192</DOCNO>
	<brief_summary>PRIMAVERA Phase IIa clinical trial , objective ass immunologic response HPV vaccine population immunocompromised girl . The principal hypothesis immunologic response tetravalent vaccine girl receive immunosuppressive treatment comparable immunologic response girl immunosuppressed .</brief_summary>
	<brief_title>Multicenter Trial Evaluating Immunogenicity HPV Vaccination Girls Immunosuppressive Therapy .</brief_title>
	<detailed_description>The human papillomaviruses ( HPV ) cause common sexually transmitted infection . Among oncogenic HPV , HPV 16 18 find 70 % invasive cancer . Among non-oncogenic HPV , HPV 6 11 find 90 % anogenital wart . Two prophylactic vaccine currently available : Gardasil ® protect HPV 6 , 11 , 16 18 Cervarix ® protect HPV16 18 . Gardasil ® indicate prevention high-grade cervical dysplasia ( CIN2-3 ) , cancer cervix , high-grade dysplasia vulva ( VIN2-3 ) genital wart . The choice Gardasil ® link theoretical risk graft rejection bivalent vaccine , fact frequency anogenital wart relate HPV 6 11 increase immunocompromised population . The immunosuppressed woman likely present abnormal cervical smear general population . A notice age vaccination HPV girl receive transplant make High Council Public Health , recommend vaccination HPV could offer girl benefit transplant age 14 year accord data MA . The High Council Public Health also renew request study conduct specifically vaccination girl young woman , immunocompromised , include receive immunosuppressive therapy . The primary objective evaluate persistence immunological response tetravalent HPV vaccine 18 month first dose vaccine .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Female gender Age ≥ 9 year &lt; 18 year Weight ≥ 25 kg Solid organ transplantation : kidney , liver , heart , lung , intestinal combine transplant ; systemic lupus erythematosus systemic immune disease Transplantation diagnosis lupus diagnosis systemic immune disease since 6 month Immunosuppressant treatment antimetabolites calcineurin inhibitor , without associate corticosteroid Minimum require period 3 month consider stable transplantation without relapse lupus accord physician evaluation In case sexual activity ( assessed autodeclaration ) : onset le one year inclusion Written inform consent sign investigator legal representative patient , assent patient Male gender Pregnancy Age &lt; 9 year ≥ 18 year Previous HPV vaccination Immunosuppressive treatment antiTNF ( adalimumab , etanercept , infliximab ) monoclonal antibody ( rituximab , anakinra , abatacept ) last 3 month Active malignancy Active opportunistic infection HIV infection Concurrent clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Seroconversion</keyword>
	<keyword>Immunosuppressed treatment</keyword>
	<keyword>HPV vaccination</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>